Nano-Targeting of Mucosal Addressin Cell Adhesion Molecule-1 Identifies Bowel Inflammation Foci in Murine Model

Truffi, Marta; Colombo, Miriam; Peñaranda-Avila, Jesus; Sorrentino, Luca; Colombo, Francesco; Monieri, Matteo; Collico, Veronica; Zerbi, Pietro; Longhi, Erika; Allevi, Raffaele; Prosperi, Davide; Corsi, Fabio

doi:10.2217/nnm-2017-0004

Cited by 12 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colony formation assay. colon cancer SW480 and T84 cells (1,000 cells/dish) were seeded in 3.5 cm dishes and cultured in a humidified environment with 5% CO 2 at 37˚C for 24 h. Then, different concentrations of scutellarein (10,20,40,60 and 80 µM) were added into each dish and the cells were incubated with scutellarein at 37˚C for 15 days. Cells treated with dMSO were used as the negative control.…”

Section: Methodsmentioning

confidence: 99%

“…The increased expression of McAM in the primary tumor types is associated with metastasis and prognosis in several cancer types (16)(17)(18). Mucosal addressin cell adhesion molecule 1 (Madcam1) is known as a type of adhesion molecule, which is involved in inflammatory responses with no expression in the majority of normal tissues (19,20). Receptor for advanced glycation end products (RAGE) is a signal transduction receptor that is involved in multiple pathologic conditions, including carcinogenesis and inflammation relying on its diverse ligands (21,22).…”

Section: Scutellarein Inhibits the Development Of Colon Cancer Via CDmentioning

confidence: 99%

See 1 more Smart Citation

Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination

Wang

Zhong

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

Scutellarein has been identified to serve an anti-tumor function in human colon cancer, but the underlying mechanisms remain largely unclear. The present study further investigated the effect and mechanism of scutellarein, extracted from wild chrysanthemum, in the progression of colon cancer. MTT, clone formation, flow cytometry and tumor-bearing mice assays were used to detect cell viability, clone formation, apoptosis and tumorigenesis, respectively. Western blot and quantitative PcR assays were performed for protein and mRNA expression detection. The results revealed that, compared with the control group, scutellarein treatment significantly inhibited the viability and induced the apoptosis of colon cancer cells (P<0.05), with significant decreases in receptor for advanced glycosylation end products (RAGE) protein expression and stability and an increase in RAGE ubiquitination (P<0.05). However, the effects of scutellarein exerted in cell apoptosis and viability were rescued by RAGE overexpression, and accelerated by RAGE knockdown. Additionally, it was observed that scutellarein treatment induced a significant increase in the expression of cell division control protein 4 (cdc4) compared with the control group (P<0.05), which was then verified to interact with RAGE protein and mediate its ubiquitination. Overexpression of cdc4 inhibited colon cancer cell viability and promoted the apoptosis of SW480 and T84 cells, whereas this function was weakened when RAGE was overexpressed. Furthermore, CDC4 downregulation significantly neutralized scutellarein functions in promoting cell apoptosis and inhibiting cell viability and tumorigenesis in colon cancer cells compared with the scutellarein group (P<0.05). In conclusion, the present study revealed that scutellarein inhibited the development of colon cancer through upregulating cdc4-mediated RAGE ubiquitination.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Scutellarein Inhibits the Development Of Colon Cancer Via CDmentioning

confidence: 99%

Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination

Wang

Zhong

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…81 In another study, Truffi et al developed anti-MAdCAM-1 antibody-functionalized MnO nanoparticles with low toxicity. 82 By actively targeting the MAdCAM-1, the MnO nanoparticles achieved enhanced accumulation in the inflamed bowel sites in a murine model of acute colitis.…”

Section: Active Targetingmentioning

confidence: 99%

“…Imaging has long been utilized to evaluate segments of the digestive tract that are inaccessible with conventional endoscopy. For decades, nanoparticles such as Au, 116,117 Fe and Au complexes, 118 quantum dots, 119,120 MnO, 82 and lipid nanoparticles 74 have been developed and used in cancer imaging and diagnosis. During traditional clinical CT imaging, iodinated small molecules and barium sulfate suspensions are usually used as contrast agents, 121,122 but they are not ideal for imaging IBD due to their nonspecificity.…”

Section: Nanocarriers Mediate Precise Diagnoses Of Ibdmentioning

confidence: 99%

Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease

Wang¹,

Yu²,

Yang³

2021

JIR

View full text Add to dashboard Cite

The effective colon drug delivery remains to be an international frontier research in inflammatory bowel disease (IBD) therapy. The exploration and research of nanocarrier-based nanomedicine with great potential brings new opportunities for IBD therapy and diagnoses. Functional nanocarriers with varying morphology and characteristics can not only effectively avoid the destruction of the complex gastrointestinal (GI) tract microenvironment but also endow drugs with target therapy and improved bioavailability, thus elevating therapeutic efﬁcacy. In this review, we illustrated several challenges in IBD therapy, then emphasis on some latest research progress of nanoparticles based therapy of oral administration, rectal administration and parenteral administration, as well as IBD diagnoses. Finally, we described the future perspective of nanocarriers in the treatment and diagnoses of IBD.

show abstract

“…Due to their size and versatility, nanoparticles have attracted interest in the field of anticancer medicine, and they have shown ability to deliver consistent amounts of drugs and control their release at the tumor site [14,15,16,17,18]. Interesting feature of nanoparticles and nano-systems is the possibility to chemically or genetically modify their surface with a variety of targeting moieties or active ligands in order to trigger specific direction and recognition of the biological target [19,20,21]. The aim of the present paper is to review the current state-of-the-art and future translational perspectives on nano-strategies to target breast cancer microenvironment.…”

Section: Introductionmentioning

confidence: 99%

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy

Truffi

Mazzucchelli

Bonizzi

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

Cancer-associated fibroblasts (CAF) are the most abundant cells of the tumor stroma and they critically influence cancer growth through control of the surrounding tumor microenvironment (TME). CAF-orchestrated reactive stroma, composed of pro-tumorigenic cytokines and growth factors, matrix components, neovessels, and deregulated immune cells, is associated with poor prognosis in multiple carcinomas, including breast cancer. Therefore, beyond cancer cells killing, researchers are currently focusing on TME as strategy to fight breast cancer. In recent years, nanomedicine has provided a number of smart delivery systems based on active targeting of breast CAF and immune-mediated overcome of chemoresistance. Many efforts have been made both to eradicate breast CAF and to reshape their identity and function. Nano-strategies for CAF targeting profoundly contribute to enhance chemosensitivity of breast tumors, enabling access of cytotoxic T-cells and reducing immunosuppressive signals. TME rearrangement also includes reorganization of the extracellular matrix to enhance permeability to chemotherapeutics, and nano-systems for smart coupling of chemo- and immune-therapy, by increasing immunogenicity and stimulating antitumor immunity. The present paper reviews the current state-of-the-art on nano-strategies to target breast CAF and TME. Finally, we consider and discuss future translational perspectives of proposed nano-strategies for clinical application in breast cancer.

show abstract

Nano-Targeting of Mucosal Addressin Cell Adhesion Molecule-1 Identifies Bowel Inflammation Foci in Murine Model

Abstract: Anti-MAdCAM-1 functionalized nanoparticles detected active bowel inflammation foci, accurately following MAdCAM-1 expression pattern. These nanoconjugates could be a promising noninvasive imaging system for an early and accurate follow-up in patients affected by acute colitis.

Cited by 12 publications

References 51 publications

Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination

Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination

Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy

Contact Info

Product

Resources

About